Evidence review
Preventing muscle loss on a GLP-1: what the evidence says
GLP-1 weight loss includes some lean mass — here's what the trial data shows, and what protein intake and resistance training evidence says about limiting it.
In this brief
The Desk's #1 pick
CoreAge Rx
94 · AOne price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
Visit CoreAge Rx- Semaglutide
- $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published
- Tirzepatide
- $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published
- Coverage
- US only; restrictions by state, confirmed at intake
- Access
- Compounded
Advertising disclosure · we may earn a commission at no extra cost to you. It never changes a Brief Score — but it is why these two providers are the ones in this box.
Also here
Telos Rx
85 · BThe widest published catalog in our ranking (telosrx.com): compounded semaglutide and tirzepatide in oral and microdosed forms, plus intranasal NAD+, recovery peptides and bioidentical HRT — all compounded, none FDA-approved, on a LegitScript-certified platform.
Visit Telos RxGLP-1s are remarkably effective at reducing weight, but the number on the scale doesn't tell you what kind of weight you lost. A meaningful share of it, for most people, is lean mass — including muscle — and that's worth planning for rather than discovering after the fact.
What the trial data actually shows
In the SURMOUNT-1 body composition sub-study, tirzepatide-treated participants lost significant fat mass, but a portion of total weight lost was lean mass as well, roughly in line with what's typically seen during any substantial weight loss, whether from a GLP-1, surgery, or diet alone2. A broader review of lean mass changes across GLP-1-based therapies found this pattern is consistent across the drug class, not unique to any single molecule, and highlighted mitigation strategies as an active area of both research and clinical practice1. A network meta-analysis of GLP-1 and dual-agonist trials confirmed the same overall pattern: substantial fat loss alongside a real, non-trivial reduction in fat-free mass5.
Why this matters beyond the scale
Muscle isn't just about strength — it's metabolically active tissue that affects your resting energy expenditure, and losing a disproportionate amount of it during rapid weight loss can work against you over time, including making a weight-loss plateau more likely as your body's overall energy needs drop. It also matters for how you look and function once you've lost the weight — the difference between 'smaller' and 'leaner' comes down largely to how much of what you lost was fat versus muscle, and the same rapid-loss dynamic behind lean mass loss is also the leading explanation for facial volume loss ('Ozempic face') and, for some people, temporary hair shedding — adequate protein intake is a lever that plausibly helps with all three, not just the number on the scale. This concern grows with age, where preserving muscle mass and strength has its own independent health stakes separate from weight management.
What the evidence says actually helps
Two levers have real evidence behind them. First, protein intake: standard sports-nutrition guidance recommends a higher relative protein intake during any calorie deficit specifically to protect lean mass, and that guidance applies directly to a GLP-1-driven deficit3. Because appetite suppression can make it genuinely hard to eat enough protein, prioritizing protein-dense foods earlier in a meal — before you feel full — is a practical way to hit that target on a reduced overall intake. Second, resistance training: a review specifically examining incretin-based weight-loss pharmacotherapy alongside exercise found resistance training is a promising, evidence-supported way to help preserve lean mass and optimize body composition during treatment, distinct from cardio alone4. Neither habit needs to be extreme — consistent resistance training two to three times a week and a genuine effort to hit a higher protein target both have real support behind them.
What this doesn't mean
This isn't a reason to avoid GLP-1 treatment, and it doesn't mean muscle loss is inevitable or catastrophic — most people on these drugs still come out net ahead on body composition, with far more fat lost than muscle. It's a reason to be proactive rather than passive about the two things you can actually control: what you're eating and whether you're doing any resistance training at all.
Where this fits with the rest of your plan
This concern is closely tied to the shape of your overall weight-loss timeline — body composition shifts happen throughout treatment, not just at the end — and to how your dose is titrated, since appetite suppression intensity changes as you move through semaglutide or tirzepatide dosing. It's also relevant if you're weighing whether or when to stop treatment, since regained weight after discontinuation doesn't always come back as the same tissue you lost — see stopping a GLP-1: regain risk, explained. This is general nutrition and exercise information, not individualized medical advice — a registered dietitian or your prescriber can help tailor a protein and training plan to your situation.
Frequently asked questions
Do GLP-1s cause muscle loss?
Trial body-composition data shows most weight lost on a GLP-1 is fat, but a real, non-trivial portion is lean mass, including muscle — a pattern consistent across the drug class and similar to what's seen with any substantial weight loss, not unique to GLP-1s.
How much protein should I eat on a GLP-1?
There's no single universal number, but standard sports-nutrition guidance supports higher relative protein intake during any calorie deficit to protect lean mass. Because appetite suppression makes eating enough harder, prioritizing protein early in meals is a practical way to hit that target.
Does resistance training actually help?
Evidence reviews specifically looking at GLP-1 pharmacotherapy alongside exercise point to resistance training as a promising way to help preserve lean mass during treatment, distinct from cardio alone. Two to three sessions a week is a reasonable, evidence-supported target.
Should I be worried about muscle loss on a GLP-1?
Not to the point of avoiding treatment — most people still come out with far more fat lost than muscle. It's a reason to be proactive about protein intake and resistance training, not a reason to reconsider the medication itself.
References
- Neeland IJ, Linge J, Birkenfeld AL (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/38937282/
- Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/39996356/
- Aragon AA, Schoenfeld BJ, Wildman R, et al. (2017). International society of sports nutrition position stand: diets and body composition. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/28630601/
- Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, Green DJ (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes Care. https://pubmed.ncbi.nlm.nih.gov/38687506/
- Karakasis P, Patoulias D, Fragakis N, Mantzoros CS (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. https://pubmed.ncbi.nlm.nih.gov/39719170/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
GLP-1 for PCOS: what the evidence shows
What the trial evidence actually shows about GLP-1 receptor agonists for PCOS — weight, insulin resistance, hormonal markers, and what's still off-label.
ReadStopping a GLP-1: regain risk and what happens after you quit
What the trial evidence actually shows about weight regain after stopping semaglutide or tirzepatide, why it happens, and what to consider before quitting.
ReadGLP-1 microdosing: what it is, and what evidence actually supports it
GLP-1 microdosing means taking below the labeled starting dose long-term. Here's what dose-response trial data actually shows, and what isn't studied at all.
ReadGLP-1 and alcohol: what the interaction risk actually is
What actually happens when you drink alcohol on a GLP-1 — GI interaction, hypoglycemia risk, and the emerging trial evidence on reduced alcohol craving.
ReadRetatrutide: what the trial data shows (and why you can't legally buy it yet)
Retatrutide's phase 2 data is genuinely striking, and it's not an FDA-approved drug. What the trials show, and why sourcing it isn't like sourcing a GLP-1.
ReadGLP-1s and pancreatitis: what the evidence actually shows
Every GLP-1 label warns about acute pancreatitis. Here's what a 2026 dose-response meta-analysis and a large real-world cohort actually found about the risk.
Read